Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.24M Buy
9,280
+4,980
+116% +$564K 0.25% 50
2026
Q1
$479K Buy
4,300
+1,000
+30% +$118K 0.11% 62
2025
Q4
$445K Buy
+3,300
New +$360K 0.09% 63

Other funds holding ABVX

Harvey Capital Management's ABVX Position: Q2 2026 in Review

Harvey Capital Management increased its Abivax (ABVX) stake by 116% in Q2 2026, buying an estimated $564K and bringing the position to 9,280 shares worth $1.24M. The position accounts for 0.25% of the portfolio, ranked #50.

Harvey Capital Management first reported a position in ABVX in Q4 2025 and has held it in 3 quarters since. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Harvey Capital Management held 9,280 shares of Abivax worth $1.24M as of Q2 2026.
  • Harvey Capital Management bought 4,980 Abivax shares in Q2 2026, an estimated $564K.
  • Abivax made up 0.25% of Harvey Capital Management's portfolio in Q2 2026, its #50 holding.
  • Harvey Capital Management first reported a position in Abivax in Q4 2025 and has held it in 3 quarters since.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Harvey Capital Management's 13F filing for Q2 2026, filed 17 Aug 2026.